ABIRATERONE ACETATE

SynDRA canonical compound SYN0009160 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	CYP17A1 \| CYP2C19 \| CYP2C8 \| CYP3A5
Mechanism of action	androgen biosynthesis inhibitor
Indication	prostate cancer
Disease area	oncology

All known targets

zytiga
CB-7630
CB7630
NSC-748121
NSC-749227
Abiraterone accord
Abiraterone acetate component of akeega
Abiraterone krka
Abiraterone mylan
Yonsa
Zytiga
JNJ-212082
BRD-K24048528
abiraterone-acetate
Abiraterone
CB-7598
(3beta)-17-(3-pyridinyl)-androsta-5,16-dien-3-ol
17-(3-Pyridyl)androsta-5,16-dien-3beta-ol
Abiraterone (CB-7598)
CB7598
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
CHEMBL254328
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol
CHEBI:68642
154229-19-3 (Abiraterone)
(3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol
G819A456D0
NSC 741232
Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3b)-
17-(3-Pyridyl)androsta-5,16-dien-3.beta.-ol
17-(pyridin-3-yl)androsta-5,16-dien-3beta-ol
(1S,2R,5S,10R,11S,15S)-2,15-dimethyl-14-(pyridin-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-7,13-dien-5-ol
(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol.
Abiraterone [INN:BAN]
UNII-G819A456D0
Abiraterone- Bio-X
MFCD00924100
Androsta-5,16-dien-3-ol, 17-(3-pyridinyl)-, (3beta)-